SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Has Filed in U.S. District Court to Recover Losses Suffered by Investors in Argos Therapeutics, Inc.

Wednesday, March 15, 2017 6:13 PM UTC

NEW YORK, March 15, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired shares of Argos Therapeutics, Inc. (“Argos”) (NASDAQ:ARGS) between February 7, 2014 and February 21, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Maurer v. Argos Therapeutics, Inc., et al. (Case No. 1:17-cv-216) in the USDC for the Middle District of North Carolina. Click here to view the complaint. To get more information go to:

http://www.zlk.com/pslra/argos-therapeutics-inc

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

Argos’ product candidate AGS-003 (rocapuldencel-T) is being evaluated in a pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). The complaint alleges that Argos issued materially false and/or misleading statements, causing the stock to trade at artificially inflated prices; following the release of adverse information, shares of Argos plummeted, damaging investors. In particular, the complaint alleges that Argos issued materially false and/or misleading information regarding the success and potential of its drug candidate AGS-003 (rocapuldencel-T).

On February 22, 2017, despite positive statements made by the Company, Argos then announced that the ADAPT study would be discontinued for futility. Following this news, shares of Argos fell approximately 66% to close at $1.48 per share on February 22, 2017.

Take Action: if you suffered a loss in Argos you have until May 15, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:    
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor 
New York, NY 10004            
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Has Filed in U.S. District Court to Recover Losses Suffered by Investors in Argos Therapeutics, Inc.

Editor's Picks

Welcome to EconoTimes